N11: Complementary and alternative methods to improve quality of life in patients with inflammatory bowel diseases: a systematic literature reviewECCO'21 Virtual
Year: 2021
Authors: Martinato, M.(1);Comoretto, R.I.(1);Zampieri, A.(1);Monaco, E.(1);Barberio, B.(2);Azzolina, D.(1);Savarino, E.(2);Gregori, D.(1);
(1)University of Padova, Department of Cardiac-Thoracic-Vascular Sciences and Public Health, Padova, Italy;(2)University of Padova, Department of Surgical Oncological and Gastroenterological Sciences, Padova, Italy; Nursing Research Laboratory
N12: A decade of waiting to know is not good enough! Experiences of women with vulval Crohn’s diseaseECCO'21 Virtual
Year: 2021
Authors: Fourie, S.(1,2);Czuber-Dochan, W.(2);Jackson, D.(3);Norton, C.(2);
(1)University of Oxford, Nuffield Department of Medicine, Oxford, United Kingdom;(2)King's College London, Florence Nightingale Faculty of Nursing Midwifery and Palliative Care, London, United Kingdom;(3)University of Sydney, Faculty of Medicine and Health, Sydney, Australia
N13: Living in rural communities with Inflammatory Bowel Disease: Perspectives on healthcare use and access to care from patients and providers in one Canadian provinceECCO'21 Virtual
Year: 2021
Authors: Rohatinsky, N.(1);Russell, B.(1);Boyd, I.(2);Dickson, A.(3);Fowler, S.(4);Peña-Sánchez, J.N.(5);Quintin, C.L.(6);Risling, T.(1);Wicks, K.(7);Wicks, M.(7);
(1)University of Saskatchewan, College of Nursing, Saskatoon, Canada;(2)University of Saskatchewan, College of Nursing, Kinistino, Canada;(3)Saskatchewan Health Authority, Chronic Disease Management, Saskatoon, Canada;(4)University of Saskatchewan, College of Medicine- Gastroenterology and Hepatology, Saskatoon, Canada;(5)University of Saskatchewan, College of Medicine- Community Health and Epidemiology, Saskatoon, Canada;(6)Crohn’s and Colitis Canada, Saskatchewan, Saskatoon, Canada;(7)University of Saskatchewan, College of Nursing, Cabri, Canada
N14: The Effectiveness of patient information leaflets provided by a Clinical Nurse Specialist on disease related knowledge in Inflammatory Bowel DiseaseECCO'21 Virtual
Year: 2021
Authors: Walsh, C.(1);
(1)Letterkenny General Hospital, Gastroenterology, Letterkenny, Ireland
N15: Transition of care programme and treatment adherence in adolescents with Inflammatory Bowel DiseaseECCO'21 Virtual
Year: 2021
Authors: Garzia Stafrace, N.(1);
(1)University of Malta, Faculty of Health Sciences, Zabbar, Malta
N16: ‘Sex? Don't even remember what that is …’ exploring IBD patient engagement with online forums regarding the topics of relationships and intimacyECCO'21 Virtual
Year: 2021
Authors: Barnes, H.(1);Fourie, S.(1);
(1)Universiy of Oxford, Nuffield Department of Medicine, Oxford, United Kingdom
N17: The Perceptions and Experiences of People Living with Inflammatory Bowel Disease of Nursing Care A Qualitative Evidence SynthesisECCO'21 Virtual
Year: 2021
Authors: Conmy, C.(1);
(1)Sligo University Hospital, Gastroenterology, Sligo, Ireland
N18: Multidisciplinary team importance in the view of the patients with Inflammatory Bowel Disease in BrazilECCO'21 Virtual
Year: 2021
Authors: Herrerias, G.(1);Ribeiro, J.R.(1);Beraldo, R.F.(1);Hossne, R.S.(1);Baima, J.P.(1);Sassaki, L.Y.(1);
(1)São Paulo State University Unesp, Department of Internal Medicine, Botucatu, Brazil
OP01: Comparison of fecal transplantation, fecal transplantation with the novel UC diet or the UC diet alone for Refractory Mild to Moderate Active Ulcerative Colitis: The CRAFT UC randomized controlled trialECCO'21 Virtual
Year: 2021
Authors: Levine, A.(1,2);Scaldaferri, F.(3,4);Sarbagili Shabat, C.(1,2);Zittan, E.(5);Hirsch, A.(2,6);Mentella, M.C.(7);Musca , T.(7);Cohen, N.A.(6);Ron, Y.(6);Fliss Isakov , N.(6);Pfeffer, J.(6);Yaakov, M.(1);Fanali, C.(4);Turchini , L.(4);Masucci, L.(8,9);Quaranta, G.(8,9);Anastasia, G.(10);Weinberger, A.(10);Kopylov , U.(2,11);Maharshak, N.(2,6)
(1)Edith Wolfson Medical Center, Pediatric Gastroenterology Unit- PIBD research center, Holon, Israel;(2)Tel Aviv University, Sackler School of Medicine, Tel Aviv, Israel;(3)'A. Gemelli” IRCSS, Università Cattolica del Sacro Cuore – Fondazione PoliclinicoDipartimento di Medicina e Chirurgia Traslazionale, Rome, Italy;(4)'A. Gemelli” IRCSS, Cemad CENTER for Digestive Disease- UOC Medicina Interna e Gastroenterologia Fondazione Policlinico, Rome, Italy;(5)Haemek Medical Center, Gastroenterology Institute- IBD Unit, Afula, Israel;(6)Tel Aviv Sourasky Medical Center, Department of Gastroenterology and Hepatology, Tel Aviv, Israel;(7)'A. Gemelli” IRCSS, UOC di Nutrizione Clinica- Medicina Interna- Gastroenterologia e Oncologia Medica Fondazione Policlinico, Rome, Italy;(8)'A. Gemelli” IRCSS, Istituto di Microbiologia Università Cattolica del Sacro Cuore – Fondazione Policlinico, Rome, Italy;(9)A. Gemelli IRCCS, Dipartimento Scienze di Laboratorio e Infettivologiche- Fondazione Policlinico Universitario, Rome, Italy;(10)Weizmann Institute of Science, Department of Computer Science and Applied Mathematics, Rehovot, Israel;(11)Sheba Medical Center, Department of Gastroenterology Division, Ramat Gan, Israel
OP02: Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE studyECCO'21 Virtual
Year: 2021
Authors: Irving, P.M.(1,2);Sands, B.E.(3);Hoops, T.(4);Izanec, J.L.(4);Gao, L.L.(4);Gasink, C.(4);Greenspan, A.(4);Allez, M.(5,6);Danese, S.(7);Hanauer, S.B.(8);Jairath, V.(9,10);Kuhbacher, T.(11);Lewis, J.D.(12);Loftus Jr., E.V.(13);Mihaly, E.(14);Panaccione, R.(15);Scherl, E.(16);Shchukina, O.(17);Sandborn, W.J.(18)
(1)Guy’s and Saint Thomas’ Hospitals NHS Trust, Gastroenterology, London, United Kingdom;(2)King’s College London, School of Immunology and Microbial Sciences, London, United Kingdom;(3)Icahn School of Medicine at Mt Sinai, Gastroenterology, New York, United States;(4)Janssen Research & Development- LLC, Immunology, Horsham, United States;(5)INSERM UMRS 1160- Université de Paris, Gastroenterology, Paris, France;(6)Hôpital Saint-Louis Hospital- Assistance Publique-Hôpitaux de Paris AP-HP, Gastroenterology, Paris, France;(7)Humanitas Clinical and Research Center- Humanitas University, Inflammatory Bowel Disease Center and Department of Biomedical Sciences, Milan, Italy;(8)Northwestern University Feinberg School of Medicine, Gastroenterology, Chicago, United States;(9)Division of Gastroenterology- University Hospital, Medicine, Ontario, Canada;(10)Western University- London, Division of Epidemiology and Biostatistics, Ontario, Canada;(11)Asklepios Westklinikum Hamburg and Christian Albrechts University, Gastroenterology, Hamburg, Germany;(12)Perelman School of Medicine at the University of Pennsylvania, Gastroenterology, Philadelphia, United States;(13)Mayo Clinic College of Medicine, Gastroenterology and Hepatology, Rochester, United States;(14)Semmelweis University Medical School, 2nd Department of Internal Medicine, Budapest, Hungary;(15)University of Calgary, Inflammatory Bowel Disease Unit- Division of Gastroenterology and Hepatology, Alberta, Canada;(16)New York Presbyterian Hospital Weill Cornell Medicine, Weill Department of Medicine, New York, United States;(17)City Clinical Hospital #31, Gastroenterology, St-Petersburg, Russian Federation;(18)University of California San Diego, Gastroenterology, La Jolla, United States
OP03: Anti-SARS-CoV2 antibody responses are attenuated in patients with Inflammatory Bowel Disease treated with infliximabECCO'21 Virtual
Year: 2021
Authors: Kennedy, N.A.(1);Goodhand, J.(1);Bewshea, C.(1);Nice, R.(2);Chee, D.(1);Lin, S.(1);Chanchlani, N.(1);Butterworth, J.(3);Cooney, R.(4);Croft, N.(5);Hart, A.(6);Irving, P.(7);Kok, K.(8);Lamb, C.(9);Limdi, J.(10);MacDonald, J.(11);McGovern, D.(12);Mehta, S.(13);Murray, C.(14);Patel, K.(15);Pollok, R.(15);Raine, T.(16);Russell, R.(17);Selinger, C.(18);Smith, P.(19);Bowden, J.(20);McDonald, T.(2);Lees, C.(21);Sebastian, S.(22);Powell, N.(23);Ahmad, T.(1)
(1)Exeter IBD Pharmacogenetics, Gastroenterology, Exeter, United Kingdom;(2)Exeter Clinical Laboratory International, Biochemistry, Exeter, United Kingdom;(3)Shrewsbury and Telford Hospitals NHS Trust, Gastroenterology, Shrewsbury, United Kingdom;(4)University Hospital Birmingham NHS Foundation Trust, Gastroenterology, Birmingham, United Kingdom;(5)Royal London Hospital- Barts Health NHS Trust, Paediatric Gastroenterology, London- UK, United Kingdom;(6)St Marks Hospital and Academic Institute, Gastroenterology, London, United Kingdom;(7)Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom;(8)Royal London Hospital- Barts Health NHS Trust, Gastroenterology, London, United Kingdom;(9)Newcastle upon Tyne Hospitals NHS Foundation Trust, Gastroenterology, Newcastle upon Tyne, United Kingdom;(10)Pennine Acute Hospitals NHS Trust, Gastroenterology, Manchester, United Kingdom;(11)Queen Elizabeth University Hospital- NHS Greater Glasgow and Clyde, Gastroenterology, Glasgow, United Kingdom;(12)F. Widjaja Foundation Inflammatory Bowel and Immunology Research Institute, Cedars-Sinai Medical Center, California, United States;(13)University College London Hospitals NHS Foundation Trust, Gastroenterology, London, United Kingdom;(14)Royal Free London NHS Foundation Trust, Gastroenterology, London, United Kingdom;(15)St George's University Hospital NHS Foundation Trust, Gastroenterology, London, United Kingdom;(16)Addenbrooke’s Hospital- Cambridge University Hospitals NHS Foundation Trust, Gastroenterology, Cambridge, United Kingdom;(17)Royal Hospital for Sick Children- NHS Lothian, Paediatric Gastroenterology, Edinburgh, United Kingdom;(18)St James’s University Hospital- The Leeds Teaching Hospitals NHS Trust, Gastroenterology, Leeds, United Kingdom;(19)Royal Liverpool Hospital- Liverpool University Hospitals NHS Foundation Trust, Gastroenterology, Liverpool, United Kingdom;(20)University of Exeter, Medical School, Exeter, United Kingdom;(21)Western General Hospital- NHS Lothian, Gastroenterology, Edinburgh, United Kingdom;(22)Hull University Teaching Hospitals NHS Trust, Gastroenterology, Hull, United Kingdom;(23)Imperial College Healthcare NHS Trust, Gastroenterology, London, United Kingdom; CLARITY IBD Investigators
OP04: Safety analysis of filgotinib for Ulcerative Colitis: Results from the phase 2b/3 SELECTION study and phase 3 SELECTIONLTE long-term extension studyECCO'21 Virtual
Year: 2021
Authors: Schreiber, S.W.(1);Watanabe, M.(2);Yun, C.(3);Zhou, Y.(3);Zhao, S.(3);Hsieh, J.(3);Moerch, U.(4);Rogler, G.(5);Loftus Jr, E.V.(6)
(1)Kiel University, Department of Medicine I, Kiel, Germany;(2)Tokyo Medical and Dental University, TMDU Advanced Research Institute, Tokyo, Japan;(3)Gilead Sciences, Inc., Foster City, United States;(4)Gilead Sciences, Inc., Copenhagen, Denmark;(5)University Hospital of Zurich- University of Zurich, Clinic for Gastroenterology and Hepatology, Zurich, Switzerland;(6)Mayo Clinic, Department of Internal Medicine- Division of Gastroenterology and Hepatology, Rochester- MN, United States
OP05: Association of ultra-processed food intake with risk of Inflammatory Bowel Disease from the prospective urban rural epidemiology (PURE) study: A prospective cohort studyECCO'21 Virtual
Year: 2021
Authors: Narula, N.(1);Wong, E.(1);Dehghan, M.(2);Mente, A.(2);Rangarajan, S.(2);Marshall, J.(1);Moayyedi, P.(1);Reinisch, W.(3);Yusuf, S.(2)
(1)McMaster University, Department of Medicine- Division of Gastroenterology, Hamilton, Canada;(2)McMaster University and Hamilton Health Sciences, Population Health Research Institute, Hamilton, Canada;(3)Medical University of Vienna, Department of Internal Medicine III- Division of Gastroenterology and Hepatology, Vienna, Austria
OP06: 5-aminosalicylates are not associated with adverse outcomes in Inflammatory Bowel Disease patients with COVID-19: Analysis from an international registryECCO'21 Virtual
Year: 2021
Authors: Ungaro, R.(1);Brenner, E.(2);Agrawal, M.(1);Gearry, R.B.(3);Kaplan, G.G.(4);Kissous-Hunt, M.(1);Ng, S.C.(5);Rahier, J.F.(6);Reinisch, W.(7);Steinwurz, F.(8);Zhang, X.(2);Lewis, J.D.(9);Kappelman, M.D.(2);Colombel, J.F.(1)
(1)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York City, United States;(2)University of North Carolina at Chapel Hill, Division of Pediatric Gastroenterology- Department of Pediatrics, Chapel Hill- North Carolina, United States;(3)University of Otago, Department of Medicine, Christchurch, New Zealand;(4)University of Calgary, Departments of Medicine and Community Health Sciences, Calgary- Alberta, Canada;(5)Li Ka Shing Institute of Health Science- The Chinese University of Hong Kong, Department of Medicine and Therapeutics- State Key Laboratory of Digestive Disease, Hong Kong, China;(6)Université Catholique de Louvain, Department of Gastroenterology, Yvoir, Belgium;(7)Medical University of Vienna, Department Internal Medicine III- Division Gastroenterology & Hepatology, Vienna, Austria;(8)Hospital Israelita Albert Einstein, Gastroenterology, São Paulo, Brazil;(9)The University of Pennsylvania, Division of Gastroenterology, Philadelphia- Pennsylvania, United States
OP07: Artificial intelligence surpasses gastrointestinal experts in the classification of endoscopic severity among Ulcerative ColitisECCO'21 Virtual
Year: 2021
Authors: Lo, B.Z.S.(1);Liu, Z.(1,2);Bendtsen, F.(1);Igel, C.(2);Vind, I.(1);Burisch, J.(1)
(1)Copenhagen University Hospital Hvidovre, The Gastrounit, Hvidovre, Denmark;(2)University of Copenhagen, Department of Computer Science, Copenhagen, Denmark The Presager Project
OP08: Automatic detection of enteric ulcers and erosions in capsule endoscopy using a convolutional neural networkECCO'21 Virtual
Year: 2021
Authors: SaraivaJr., M.(1);Afonso, J.(1);Ribeiro, T.(1);Cardoso, H.(1);Ferreira, J.(2);Andrade, P.(1);Jorge, R.(2);Lopes, S.(1);Macedo, G.(1)
(1)Centro Hospitalar Universitário de S. João- EPE, Gastroenterology, Porto, Portugal;(2)Faculdade de Engenharia da Universidade do Port, Mechanical Engineering, Porto, Portugal
OP09: Patient reported outcomes reflect histologic disease activity in patients with Ulcerative Colitis: Interim analysis of the APOLLO studyECCO'21 Virtual
Year: 2021
Authors: Verstockt, B.(1,2,3);Jorissen, C.(1,2);Hoefkens, E.(1);Lembrechts, N.(1);Pouillon, L.(1);Bossuyt, P.(1,2)
(1)Imelda General Hospital, Imelda GI Clinical Research Center, Bonheiden, Belgium;(2)University Hospitals Leuven, Dpt. Gastroenterology and Hepatology, Leuven, Belgium;(3)KU Leuven, Dpt. Chronic Diseases- Metabolism and Ageing- TARGID-IBD, Leuven, Belgium
OP10: Response to biologics in IBD patients assessed by Computerized image analysis of Probe Based Confocal Laser Endomicroscopy with molecular labeling and gene expression profilingECCO'21 Virtual
Year: 2021
Authors: Iacucci, M.(1,2,3);Jeffery, L.(1);Acharjee, A.(4);Nardone, O.M.(1);Smith, S.C.(1);Labarile, N.(1);Zardo, D.(5);Cannatelli, R.(1);Shivaji, U.N.(1);Ungar, B.(1);Buda, A.(6);Grisan, E.(7);Gkoutos, G.(4);Subrata, G.(1,2,3)
(1)University of Birmingham, Institute of Translational Medicine and Institute of Immunology and Immunotherapy, Birmingham, United Kingdom;(2)University Hospitals Birmingham NHS Trust, NIHR Biomedical Research Centre, Birmingham, United Kingdom;(3)University Hospitals Birmingham NHS Trust, NIHR Wellcome Trust Clinical Research Facilities, Birmingham, United Kingdom;(4)University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom;(5)University Hospitals Birmingham NHS Trust, Department of Pathology, Birmingham, United Kingdom;(6)S. Maria del Prato Hospital- Feltre, Department of Gastrointestinal Oncological Surgery, Feltre, Italy;(7)London South Bank University, School of Engineering, London, United Kingdom
OP11: Longitudinal profiling of mucosal immune cell composition using multiplex immunohistochemistry identifies drug- and response-specific patterns in Ulcerative ColitisECCO'21 Virtual
Year: 2021
Authors: Volk, V.(1);Aden, K.(2);Tran, F.(2);Mishra, N.(3);Bernardes, J.(3);Röcken, C.(4);Schreiber, S.(2);Feuerhake, F.(1);Rosenstiel, P.(3)
(1)Hannover Medical School, Institute for Pathology, Hannover, Germany;(2)Kiel University and University Medical Center Schleswig-Holstein- Campus Kiel, Institute of Clinical Molecular Biology and Department of Internal Medicine I, Kiel, Germany;(3)Kiel University and University Medical Center Schleswig-Holstein- Campus Kiel, Institute of Clinical Molecular Biology, Kiel, Germany;(4)Kiel University and University Medical Center Schleswig-Holstein- Campus Kiel, Department of Pathology, Kiel, Germany
OP12: Blood proteins related to immunoregulation or cellular junctions reveal distinct biological profiles associated with the risk of short-term versus mid/long-term relapse in Crohn’s Disease patients stopping infliximabECCO'21 Virtual
Year: 2021
Authors: Pierre , N.(1);Huynh-Thu , V.A.(2);Allez , M.(3);Bouhnik , Y.(4);Laharie , D.(5);Bourreille , A.(6);Colombel , J.F.(7);Meuwis , M.A.(1);Louis , E.(1)
(1)GIGA-R- University of Liège, Laboratory of Translational Gastroenterology, Liège, Belgium;(2)University of Liege, Department of Electrical Engineering and Computer Science, Liège, Belgium;(3)Université de Paris, Service d’Hépato-Gastroentérologie- Hôpital Saint Louis- APHP, Paris, France;(4)Hôpital Beaujon, Service de Gastroentérologie et Assistance Nutritive, Clichy, France;(5)Centre Hospitalier Universitaire de Bordeaux, Service d’Hépato-Gastroentérologie, Bordeaux, France;(6)Centre Hospitalier Universitaire de Nantes, Institut des maladies de l’appareil digestif, Nantes, France;(7)Icahn School of Medicine at Mount Sina, Division of Gastroenterology, New York, United States GETAID (Groupe d’Etude Thérapeutique des Affections Inflammatoires du tube Digestif)